Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Sphingosine-1-Phosphate Receptors
More Information »Sphingosine-1-phosphate (S1P) receptors are a group of G-protein-coupled receptors that are currently divided into five subtypes; S1P1, S1P2, S1P3, S1P4 and S1P5. They are expressed in a wide variety of tissues, with each subtype exhibiting a different cell specificity.
Sphingosine-1-Phosphate Receptor Products
Agonists |
|
Cat.No. |
Product Name / Activity |
| 4543 |
CS 2100
|
| Selective S1P1 agonist | |
| 4677 |
CYM 50260
|
| Potent and selective S1P4 agonist | |
| 4678 |
CYM 50308
|
| Potent and selective S1P4 agonist | |
| 3601 | CYM 5442 hydrochloride |
| Selective S1P1 receptor agonist | |
| 4289 | RP 001 hydrochloride |
| Potent S1P1 agonist | |
| 2284 | SEW 2871 |
| Cell-permeable, selective S1P1 receptor agonist | |
| 1370 | Sphingosine-1-phosphate |
| Endogenous agonist at S1P1-5 | |
| 4363 | TC-SP 14 |
| Potent S1P1 receptor agonist | |
Antagonists |
|
Cat.No. |
Product Name / Activity |
| 2392 | JTE 013 |
| S1P2 receptor antagonist | |
| 4195 | VPC 23019 |
| S1P1 and S1P3 antagonist | |
| 3602 | W146 |
| Potent and selective S1P1 receptor antagonist | |
Related Categories
Quick Order
Find multiple products by catalog number
Cardiovascular Guide
Request your free copy
Highlights over 250 products for cardiovascular research. Request a copy or view PDF today.
Cancer Research Guide
Request your free copy
Highlights over 350 products for cancer research. Request a copy or view PDF today.
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
VEGF Pathway & Anti-Angiogenic Therapy
Written by N. Ferrara & Y. Crawford
A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.